Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.6088
-0.0182 (-2.90%)
At close: Dec 12, 2025, 4:00 PM EST
0.5900
-0.0188 (-3.09%)
After-hours: Dec 12, 2025, 7:57 PM EST
Longeveron Revenue
Longeveron had revenue of $137.00K in the quarter ending September 30, 2025, a decrease of -82.28%. This brings the company's revenue in the last twelve months to $1.44M, up 33.67% year-over-year. In the year 2024, Longeveron had annual revenue of $2.39M with 237.38% growth.
Revenue (ttm)
$1.44M
Revenue Growth
+33.67%
P/S Ratio
6.70
Revenue / Employee
$57,480
Employees
25
Market Cap
12.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LGVN News
- 11 days ago - Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - GlobeNewsWire
- 11 days ago - Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 24 days ago - Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 4 weeks ago - Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy - GlobeNewsWire
- 5 weeks ago - Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect - GlobeNewsWire
- 2 months ago - Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 2 months ago - Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa - GlobeNewsWire